GoodRx Price Forecast

 

GoodRx (NASDAQ: GDRX) Price Forecast

GoodRx is a healthcare savings platform that helps consumers find prescription discounts. Analyst sentiment in 2026 remains mixed, with most firms rating the stock as a Hold, but several analysts see meaningful upside from current levels.

Scenario	12-Month Price Target
Bear Case	$2.25–$2.75
Base Case	$3.15–$3.80
Bull Case	$4.00–$6.00

Current analyst averages:

• Average target around $3.18–$3.81 per analyst surveys.
• Highest published targets are near $4.00–$6.00.
• Consensus rating remains Hold/Neutral.

Bullish Factors

• Improving profitability and earnings growth forecasts for 2026–2027.
• New subscription offerings could diversify revenue.
• Recent analyst target increases from firms including Citigroup and TD Cowen.

Risks

• Revenue growth remains relatively modest.
• Competition in digital healthcare and prescription savings remains intense.
• Several analysts still maintain Hold or Sell ratings.

My Forecast

If GoodRx executes on its subscription strategy and maintains profitability improvements, a reasonable 12–18 month target range is $3.50–$4.50, representing roughly 30%–70% upside from recent trading levels. A sustained move above $5 would likely require stronger revenue growth than analysts currently expect.

If you'd like, I can also provide a , along with a .